Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum
For immediate release
Chicago, IL – July 18, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. LLY, Thermo Fisher Scientific Inc. TMO, TotalEnergies SE TTE, Amgen Inc. AMGN and Marathon Petroleum Corp. MPC.
Here are the highlights of FriToday’s analyst blog:
Best Stock Reports for Eli Lilly, Thermo Fisher and TotalEnergies
Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., Thermo Fisher Scientific Inc. and TotalEnergies SE. These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.
You can see all research reports from today here >>>
Eli Lily shares have outperformed the industry Zacks Large Cap Pharmaceuticals over the past year (+42.6% vs. +17.7%) on the back of a strong core drug portfolio in diabetes, autoimmune diseases and the cancer. Lilly’s revenue growth is driven by drugs like Trulicity, Taltz and others.
It regularly adds promising new pipeline assets through business development agreements. It has an exciting pipeline of potential new drugs, including tirzepatide for type II diabetes and donanemab for early-stage Alzheimer’s disease. Both candidates have multi-billion dollar sales potential.
However, generic competition for several drugs, increasing pricing pressure in the United States, mainly on key drugs, Trulicity, and price reductions in some international markets such as China, Japan and Europe are headwinds.
(You can read the full research report on Eli Lilly here >>>)
ThermoFisher shares have outperformed industry Zacks Medical – Instruments over the past year (+1.4% vs -25.8%). This reflects the company’s favorable growth prospects in the Analytical Instruments and Laboratory Products and Biopharmaceutical Services segments.
The company’s strategic acquisitions of PPD, Inc. and PeproTech bolster investor confidence. Thermo Fisher’s accelerated investments to expand biomanufacturing capacity also bolster optimism. Optimistic forecasts for 2022 indicate that this growth momentum will continue.
However, the year-over-year revenue decline in the specialty diagnostics segment is disappointing. The contraction of the two margins does not bode well either.
(You can read the full Thermo Fisher research report here >>>)
TotalEnergies stocks have gained +13.8% over the past year versus Zacks Oil and Gas – Refining and Marketing’s +36.4% gain. The company benefits from new startups, rising commodity prices, well-distributed LNG assets and an expanding upstream portfolio that is exposed to fast-growing hydrocarbon-producing regions.
TTE is rationalizing its portfolio through acquisitions, partnerships and divestitures. It regularly invests to expand the use of renewable energy and aims to achieve net zero emissions by 2050. TTE has enough cash to service its debts.
However, TTE’s profitability is likely to have been affected by the natural decline of oil and natural gas deposits. TTE remains exposed to acquisition risks as these assets contribute a significant volume of production. TTE has operations in some politically troubled regions and the ongoing conflict between Russia and Ukraine could affect profitability.
(You can read the full research report on TotalEnergies here >>>)
Other noteworthy reports we’re featuring today include Amgen Inc. and Marathon Petroleum Corp.
Why haven’t you watched Zacks best action?
Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.
Zacks names ‘only one best choice for doubling up’
From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.
It’s a little-known chemical company that’s up 65% year-on-year, but still very cheap. With relentless demand, rising earnings estimates for 2022 and $1.5 billion for stock buybacks, retail investors could step in at any time.
This company could rival or surpass other recent Zacks stocks which are expected to double, such as Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in one. year.
Free: See our best stock and our 4 finalists >>
Eli Lilly and Company (LLY): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO): Free Inventory Analysis Report
Marathon Petroleum Corporation (MPC): Free Stock Analysis Report
ADR (TTE) sponsored by TotalEnergies SE: free stock analysis report
To read this article on Zacks.com, click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
